Skip to main content
Premium Trial:

Request an Annual Quote

Aviva Systems Biology Acquires GenWay Biotech

NEW YORK (GenomeWeb) – Aviva Systems Biology said today it has acquired protein tools firm GenWay Biotech.

In a statement, Aviva CEO Peter Jiang described the purchase as part of his company's larger plan to "become a leading provider of proteomic solutions," and cited GenWay's experience and assets in protein, antibody, and ELISA production for both the research and clinical markets.

GenWay has ISO13485 accreditation for the development, validation, and production of antibodies and proteins for use in US Food and Drug Administration-regulated and CE marked products. The company also has a CAP-accredited CLIA facility through which it offers clinical laboratory services.

San Diego, California-based Aviva has traditionally focused on antibody production, producing more than 50,000 antibodies against more than 20,000 human gene products over the course of its business.

"We see opportunities to expand both ASB's and GenWay's existing businesses as a result from this acquisition," Jiang added.

Financial and other terms of the deal were not disclosed.